Paul E Pfeffer
Overview
Explore the profile of Paul E Pfeffer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Larenas-Linnemann D, Rhee C, Altraja A, Busby J, Tran T, Wang E, et al.
Tuberc Respir Dis (Seoul)
. 2025 Feb;
PMID: 39915034
The International Severe Asthma Registry (ISAR) was established in 2017 to advance the understanding of severe asthma and its management, thereby improving patient care worldwide. As the first global registry...
2.
Jackson D, Wechsler M, Jackson D, Bernstein D, Korn S, Pfeffer P, et al.
N Engl J Med
. 2024 Sep;
391(24):2337-2349.
PMID: 39248309
Background: Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. Methods: In these phase 3A, randomized, placebo-controlled replicate trials, we...
3.
Jackson D, Burhan H, Rupani H, Pfeffer P, Clifton I, Faruqi S, et al.
Clin Exp Allergy
. 2024 Jul;
54(10):734-746.
PMID: 39084909
Background: Benralizumab has been reported to lead to clinical remission of severe eosinophilic asthma (SEA) at 1 year in some patients. However, whether this is maintained over a longer term...
4.
Pfeffer P, Brown T, Chaudhuri R, Faruqi S, Gore R, Heaney L, et al.
J Allergy Clin Immunol Glob
. 2024 Jul;
3(3):100286.
PMID: 39071731
Background: Severe asthma pathology encompasses a wide range of pulmonary and extrapulmonary treatable traits with a high prevalence of comorbidities. Although asthma-specific health-related quality-of-life measures are most sensitive to changes...
5.
Busby J, Menon S, Martin N, Lipworth J, Zhang R, Burhan H, et al.
J Allergy Clin Immunol Pract
. 2024 Jul;
12(10):2785-2797.
PMID: 39032830
Background: Type 2 low-severe asthma phenotype is often a result of corticosteroid-overtreated type 2 disease owing to persistent symptoms, often unrelated to asthma and unlikely to respond to high-dose corticosteroid...
6.
Elneima O, Hurst J, Echevarria C, Quint J, Walker S, Siddiqui S, et al.
ERJ Open Res
. 2024 Jul;
10(4).
PMID: 39010888
Background: The long-term outcomes of COVID-19 hospitalisation in individuals with pre-existing airway diseases are unknown. Methods: Adult participants hospitalised for confirmed or clinically suspected COVID-19 and discharged between 5 March...
7.
Denton E, Hew M, Peters M, Upham J, Bulathsinhala L, Tran T, et al.
Allergy
. 2024 Jun;
79(10):2700-2716.
PMID: 38923444
Background: Biologic asthma therapies reduce exacerbations and long-term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence,...
8.
Neunie O, Rabbani W, Baker D, Chambers E, Pfeffer P, Kang A
Hum Antibodies
. 2024 Jun;
32(3):121-128.
PMID: 38905039
Objective: Asthma is a major global disease affecting adults and children, which can lead to hospitalization and death due to breathing difficulties. Although targeted monoclonal antibody therapies have revolutionized treatment...
9.
Scelo G, Tran T, Le T, Fageras M, Dorscheid D, Busby J, et al.
J Allergy Clin Immunol Pract
. 2024 May;
12(9):2347-2361.
PMID: 38768896
Background: Biologic effectiveness is often assessed as response, a term that eludes consistent definition. Identifying those most likely to respond in real-life has proven challenging. Objective: To explore definitions of...
10.
Porsbjerg C, Townend J, Bergeron C, Christoff G, Katsoulotos G, Larenas-Linnemann D, et al.
Front Immunol
. 2024 May;
15:1361891.
PMID: 38711495
Background: To date, studies investigating the association between pre-biologic biomarker levels and post-biologic outcomes have been limited to single biomarkers and assessment of biologic efficacy from structured clinical trials. Aim:...